Synchron Raises $200 Million to Advance Brain-Computer Interface Technology
New York-based brain-computer interface (BCI) company Synchron has secured $200 million in Series D funding, increasing its total capital to $345 million. The investment round was led by Double Point Ventures, with participation from existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
New investors include:
- Australian National Reconstruction Fund (NRF)
- T.Rx Capital
- Qatar Investment Authority (QIA)
- K5 Global
- Protocol Labs
- IQT
About Stentrode BCI
Synchron's Stentrode BCI is a non-surgical, endovascular platform designed to enhance mobility, communication, and independence for people with paralysis. The device is implanted in the brain through a catheter procedure that accesses the motor cortex via blood vessels. It records neural signals and converts brain activity into digital commands, enabling hands-free control of digital devices.
To date, the Stentrode has been implanted in 10 paralysis patients participating in clinical trials across Australia and the United States.
Use of Funds and Expansion Plans
The company plans to use the new funding to:
- Accelerate clinical trials and commercialization of its BCI technology
- Expand operations in New York, where its cognitive AI division focuses on developing models that learn directly from brain data
- Grow its engineering hub in San Diego
“The funding will help us fast-track trials and bring our Stentrode brain-computer interface to market, improving lives of individuals with paralysis.”
Author's summary: Synchron's $200M funding boosts the development and rollout of its pioneering non-surgical brain-computer interface, aiming to enhance independence for paralysis patients.